The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
No takes yet. Share an insight, caveat, or question.
Paik et al. (2006) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: